SHIRLEY, NY, Jan. 20, 2025 (GLOBE NEWSWIRE) — Evome Medical (TASE:) Technologies Inc. (the Company) (TSXV: EVMT) is pleased to announce that the Company’s Board of Directors has approved the grant of 1,000,000 restricted stock units (RSUs) to William Garbarini in connection with his appointment as Chief Operating Officer, effective November 22, 2024.

The RSUs are granted under the Company’s Amended and Restated 2023 Equity Incentive Plan, will vest over a period of 24 months, and upon vesting will settle into the Company’s common shares. The RSUs and the underlying common shares are Žsubject to a four Žmonth and one day hold period in accordance with Canadian securities laws and the policies of the TSX Venture Exchange.

For more information please contact:Ž

Mike Seckler Ž
Chief Executive Officer Ž
Phone: 1 (800) 760-6826 Ž
Email: [email protected]Ž

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of Žthe TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this Žrelease.Ž

Source: Evome Medical Technologies Inc.